3Nong P, Cucherat M, Boissel JP. Implication of evidence-based medicine in prescription guidelines taught to French medical students: current status in the cardiovascular field[J]. Clin Pharmacol Ther, 1999,66:173-184.
5Hong SY, Yang JO, Lee EY, et al. Effect of haemoperfusion on plasma paraquat concentration in vitro and in vivo. Toxicol Ind Health,2003, 19(1): 17-23
6Pond SM, Rivory LP, Hampson EC, et al. Kinetics of toxic doses of paraquat and the effects of hemoperfusion in the dog. J Toxicol Clin Toxicol, 1993, 31(2): 229-246
7Yang TS, Chang YL, Yen CK. Haemop- erfusion treatment in pigs experimentally intoxicated by paraquat. Hum Exp Toxicol,1997, 16 (12) : 709-715
8Hampson EC, Pond SM. Failure of haemoperfusion and haemodialysis to prevent death in paraquat poisoning. A retrospective review of 42 patients. Med Toxicol Adverse Drug Exp,1988, 3(1): 64-71
9Nakamura T, Ushiyama C, Shimada N, et al. Changes in concentrations of type IV collagen and tissue inhibitor of metalloproteinase- 1 in patients with paraquat poisoning. J Appl Toxicol, 2001, 21(6): 445-447
10Day BJ, Shawen S, Liochev SI, et al. A metalloporhyrin superoxide dismutase mimetic protects against paraquat- induced endothehial cell injury, in vivo. J Pharmacol Exp Ther,1995, 275(3): 1227-1232
